Ipek Bedir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ipek Bedir has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Dilek Telci
Yeditepe University
3 shared publications - Ayca Ece Nezir
Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University
1 shared publication - Burcu Yucel
Istanbul Medeniyet University Faculty of Medicine, Department of Medical Biology, Istanbul, Türkiye
1 shared publication - Egemen Çakırlı
Department ofPharmaceutical Technology, Faculty of Pharmacy, Acibadem Mehmet Ali Aydinlar University, 34752, Ataşehir, Istanbul,Türkiye
1 shared publication Kaan Ozturk
Yeditepe University, Department of Genetics and Bioengineering, Istanbul, Turkey; University of Münster, Institute of Cellular Virology (ICV), Münster, Germany
1 shared publication- Kaan Ozturk1 shared publication
Latest Publications
- Open Access
- 24 April 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 656
Ibuprofen and nimesulide derivatives selectively induce apoptosis in HER2-positive breast cancer via inhibition of the PLA₂–COX-2–NF-κB pathway
Background: Chronic inflammation contributes to breast cancer development through the phospholipase A₂ (PLA₂)–cyclooxygenase-2 (COX-2)–nuclear factor κB (NF-κB) cascade, which regulates prostaglandin synthesis, oxidative stress, and transcription of pro-inflammatory and anti-apoptotic genes. This pathway is particularly active in HER2-positive breast cancer, promoting proliferation, invasion, and resistance to apoptosis. Non-steroidal anti-inflammatory drugs such as ibuprofen and nimesulide target COX enzymes and have shown potential in suppressing inflammation-driven tumorigenesis. In this study, we evaluated the anticancer and anti-inflammatory activity of newly synthesized, structurally modified ibuprofen and nimesulide derivatives designed to modulate PLA₂–COX-2–NF-κB axis. Methods and Results: Cytotoxicity was assessed in HER2-positive breast cancer cells (AU565 and SKBR3) and compared with normal dermal fibroblasts (HDF) and breast epithelial cells (MCF-12A), using WST-1 assays. Apoptosis, cell cycle distribution, caspase-3/7 activation, and ROS generation were analyzed by imaging-based assays, flow cytometry, and fluorescence methods. Gene expression of PLA2G2A and PTGS2 was quantified by qRT-PCR, and NF-κB translocation was analyzed by immunocytochemistry. Two ibuprofen triazole derivative ( D1 ) and ibuprofen thioether derivative ( D7 ) and one nimesulide derivative ( D8 ) significantly reduced cell viability in a dose-dependent manner without affecting normal cells. These derivatives induced G₀/G₁ arrest, caspase-3/7 activation, ROS reduction, and increased late apoptosis. Downregulation of PLA2G2A and PTGS2 expression and inhibition of NF-κB translocation confirmed disruption of the PLA₂–COX-2–NF-κB cascade. Conclusion: These findings demonstrate that structurally optimized ibuprofen and nimesulide derivatives exert dual anti-inflammatory and anticancer effects in HER2-positive breast cancer by suppressing PLA₂–COX-2–NF-κB pathway and promoting apoptotic cell death.
- 24 April 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 656
Open AccessIbuprofen and nimesulide derivatives selectively induce apoptosis in HER2-positive breast cancer via inhibition of the PLA₂–COX-2–NF-κB pathway
Background: Chronic inflammation contributes to breast cancer development through the phospholipase A₂ (PLA₂)–cyclooxygenase-2 (COX-2)–nuclear factor κB (NF-κB) cascade, which regulates prostaglandin synthesis, oxidative stress, and transcription of pro-inflammatory and anti-apoptotic genes. This pathway is particularly active in HER2-positive breast cancer, promoting proliferation, invasion, and resistance to apoptosis. Non-steroidal anti-inflammatory drugs such as ibuprofen and nimesulide target COX enzymes and have shown potential in suppressing inflammation-driven tumorigenesis. In this study, we evaluated the anticancer and anti-inflammatory activity of newly synthesized, structurally modified ibuprofen and nimesulide derivatives designed to modulate PLA₂–COX-2–NF-κB axis. Methods and Results: Cytotoxicity was assessed in HER2-positive breast cancer cells (AU565 and SKBR3) and compared with normal dermal fibroblasts (HDF) and breast epithelial cells (MCF-12A), using WST-1 assays. Apoptosis, cell cycle distribution, caspase-3/7 activation, and ROS generation were analyzed by imaging-based assays, flow cytometry, and fluorescence methods. Gene expression of PLA2G2A and PTGS2 was quantified by qRT-PCR, and NF-κB translocation was analyzed by immunocytochemistry. Two ibuprofen triazole derivative ( D1 ) and ibuprofen thioether derivative ( D7 ) and one nimesulide derivative ( D8 ) significantly reduced cell viability in a dose-dependent manner without affecting normal cells. These derivatives induced G₀/G₁ arrest, caspase-3/7 activation, ROS reduction, and increased late apoptosis. Downregulation of PLA2G2A and PTGS2 expression and inhibition of NF-κB translocation confirmed disruption of the PLA₂–COX-2–NF-κB cascade. Conclusion: These findings demonstrate that structurally optimized ibuprofen and nimesulide derivatives exert dual anti-inflammatory and anticancer effects in HER2-positive breast cancer by suppressing PLA₂–COX-2–NF-κB pathway and promoting apoptotic cell death.
- 29 August 2024
- Published by Galenos Yayinevi in Türkiye Sağlık Enstitüleri Başkanlığı Dergisi
- Vol. 7 (2) , 71-75
The Effect of Ro48-8071 an Oxidosqualene Cyclase Inhibitor on the Proliferation of Gastric Cancer Cells
- 29 August 2024
- Published by Galenos Yayinevi in Türkiye Sağlık Enstitüleri Başkanlığı Dergisi
- Vol. 7 (2) , 71-75
The Effect of Ro48-8071 an Oxidosqualene Cyclase Inhibitor on the Proliferation of Gastric Cancer Cells
- 18 August 2023
- Published by Elsevier
- p. 137-163
Secretory phospholipase 2 (sPLA2) in carcinogenesis and tumor microenvironment
- 18 August 2023
- Published by Elsevier
- p. 137-163
Secretory phospholipase 2 (sPLA2) in carcinogenesis and tumor microenvironment